Refining endpoints in brain tumor clinical trials

被引：38

作者：

Meyers, Christina A. ^{[1
]}

Rock, Edwin P. ^{[2
]}

Fine, Howard A. ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

[2] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA

[3] NCI, Neurooncol Branch, Bethesda, MD 20892 USA

来源：

JOURNAL OF NEURO-ONCOLOGY | 2012年 / 108卷 / 02期

关键词：

Brain cancer; Clinical trials; Neurocognitive function; NEUROCOGNITIVE FUNCTION; COGNITIVE FUNCTION; PROGRESSION; RADIATION; CANCER; GLIOMA;

D O I：

10.1007/s11060-012-0813-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.

引用

页码：227 / 230

页数：4

共 50 条

[31] Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials [J].

Mallinckrodt, Craig H. ;

Lane, Peter W. ;

Schnell, Dan ;

Peng, Yahong ;

Mancuso, James P. .

DRUG INFORMATION JOURNAL, 2008, 42 (04) :303-319

[32] Recommendations for including multiple symptoms as endpoints in cancer clinical trials [J].

Cleeland, Charles S. ;

Sloan, Jeff A. ;

Cella, David ;

Chen, Connie ;

Dueck, Amylou C. ;

Janjan, Nora A. ;

Liepa, Astra M. ;

Mallick, Rajiv ;

O'Mara, Ann ;

Pearson, Jay D. ;

Torigoe, Yasuhiro ;

Wang, Xin Shelley ;

Williams, Loretta A. ;

Woodruff, Jeanie F. .

CANCER, 2013, 119 (02) :411-420

[33] Inference on multiple endpoints in clinical trials with adaptive interim analyses [J].

Kieser, M ;

Bauer, P ;

Lehmacher, W .

BIOMETRICAL JOURNAL, 1999, 41 (03) :261-277

[34] Efficacy assessment in phase I clinical trials: endpoints and challenges [J].

Gouda, M. A. ;

Ballesteros, P. A. ;

Garrido-Laguna, I. ;

Rodon, J. .

ANNALS OF ONCOLOGY, 2025, 36 (05) :507-519

[35] Choosing primary endpoints for clinical trials of health care interventions [J].

McLeod, Charlie ;

Norman, Richard ;

Litton, Edward ;

Saville, Benjamin R. ;

Webb, Steve ;

Snelling, Thomas L. .

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16

[36] Osteoporosis clinical trials endpoints: Candidate variables and clinimetric properties [J].

Cranney, A ;

Tugwell, P ;

Cummings, S ;

Sambrook, P ;

Adachi, J ;

Silman, AJ ;

Gillespie, WJ ;

Felson, DT ;

Shea, B ;

Wells, G .

JOURNAL OF RHEUMATOLOGY, 1997, 24 (06) :1222-1229

[37] Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials [J].

Craig H. Mallinckrodt ;

Peter W. Lane ;

Dan Schnell ;

Yahong Peng ;

James P. Mancuso .

Drug information journal : DIJ / Drug Information Association, 2008, 42 :303-319

[38] Blinded continuous monitoring in clinical trials with recurrent event endpoints [J].

Friede, Tim ;

Haring, Dieter A. ;

Schmidli, Heinz .

PHARMACEUTICAL STATISTICS, 2019, 18 (01) :54-64

[39] Bayesian monitoring of clinical trials with failure-time endpoints [J].

Rosner, GL .

BIOMETRICS, 2005, 61 (01) :239-245

[40] Current and future trials of the EORTC brain tumor group [J].

van den Bent, MJ ;

Stupp, R ;

Brandes, AA ;

Lacombe, D .

ONKOLOGIE, 2004, 27 (03) :246-250

← 1 2 3 4 5 →